Nuformix plc (LSE: NFX)
Health Care · Pharmaceuticals · GB
£0.00
+3.03% today · +120.0% 1Y
Nuformix plc (LSE: NFX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.87M and employs 3 people.
Over the last twelve months the share price has gained 120.0%, trading between 0.00 and 0.01.
Tweenvest scores Nuformix plc across four factors: quality 32/100. Its strongest factor is quality.
NFX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.87M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.52
- 52-week high
- £0.01
- 52-week low
- £0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.61B
- Employees
- 3
- Next earnings
- —
About Nuformix plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
- ISIN
- GB00BYW79Y38
- Listed since
- Dec 17, 2015
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.